OSE Immunotherapeutics

About:

OSE Immunotherapeutics is an integrated biotechnology company focused on inflammatory disease and cancer treatment.

Twitter/X: oseimmuno

Top Investors: Bpifrance, European Investment Bank, France 2030, Government of France, Pays de la Loire region

Description:

OSE Immunotherapeutics is a biotechnology company led by immunologists focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases, and transplantation. OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, FR104, and OSE-127 are among the company's products.

Total Funding Amount:

54M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Nantes, Pays de la Loire, France

Founded Date:

2012-01-01

Contact Email:

contact(AT)ose-immuno.com

Founders:

Emile Loria

Number of Employees:

51-100

Last Funding Date:

2024-04-10

IPO Status:

Public

Industries: